ScreenerHero

VOGX Vogenx, Inc.

NAS · US · Healthcare · Biotechnology · vogenx.com
16.16USD-1.40%Mkt Cap: 240.06M $P/E: —

Vogenx, Inc. operates as a clinical-stage drug development company that develops therapeutics for metabolic including post-bariatric hypoglycemia, or PBH, and gastroparesis. Its products include drugs, such as Mizagliflo…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$128.08BUSDP/E 29.4
MRNA
Moderna, Inc.
$78.44BUSD
REGN
Regeneron Pharmaceuticals, Inc.
$76.40BUSDP/E 18.4
ARGX
argenx SE
$57.03BUSDP/E 37.3
ARGX
argenx SE
$58.08BUSDP/E 35.4
UCB
UCB SA
$42.24BUSDP/E 18.0
RVMD
Revolution Medicines, Inc.
$43.05BUSD
ONC
BeOne Medicines AG
$41.41BUSDP/E 65.1
RPRX
Royalty Pharma plc
$32.80BUSDP/E 30.2
ALNY
Alnylam Pharmaceuticals, Inc.
$30.03BUSDP/E 37.8
ROIV
Roivant Sciences Ltd.
$25.10BUSD
BNTX
BioNTech SE
$23.93BUSD
INCY
Incyte Corporation
$22.99BUSDP/E 14.5
GMAB
Genmab A/S
$22.27BUSDP/E 30.7
GMAB
Genmab A/S
$22.54BUSDP/E 28.9
INSM
Insmed Incorporated
$22.22BUSD
ASND
Ascendis Pharma A/S
$15.03BUSDP/E 17.5
JAZZ
Jazz Pharmaceuticals plc
$15.01BUSDP/E 15.8
EXEL
Exelixis, Inc.
$14.48BUSDP/E 18.4
SMMT
Summit Therapeutics Inc.
$14.32BUSD

Key Statistics

Company
Market Cap240.06M USD
Enterprise Value244.15M USD
Revenue (TTM)—
Gross Profit—
Net Income (TTM)-1.45M USD
Revenue/Share—
Last Price16.16 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees4
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)—
PEG—
EV/EBITDA—
EV/Revenue—
P/S—
P/B-48.49
EPS (TTM)-0.22
EPS (Forward)—
52W Range
12.9513% of range38.41
52W High38.41 USD
52W Low12.95 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE157.26%
ROA-212.22%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-1.11M USD
CapEx (TTM)—
FCF Margin—
FCF Yield—
Net Debt674.68K USD
Net Debt/EBITDA—
Balance Sheet
Debt/Equity-0.89
Current Ratio0.44
Quick Ratio0.06
Book Value/Sh-0.34 USD
Cash/Share0.01 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio—
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating1.0 (Strong Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)55.00 USD
Upside (mean)+240.3%
Target Range55.00 USD – 55.00 USD
# Analysts1
Ownership
Shares Out.14.86M
Float9.81M
Insiders4.74%
Institutions12.98%
Short Interest
Short Ratio0.1d
Short % Out.0.17%
Shares Short25.52K
Short (prev mo.)25.59K
Technical
SMA 5026.92 (-40.0%)
SMA 20026.92 (-40.0%)
Beta—
S&P 52W Chg15.78%
Avg Vol (30d)140.38K
Avg Vol (10d)92.54K
Technical Indicators
RSI (14)32.6
MACD-2.6275
MACD Signal-1.0565
MACD Hist.-1.5710
BB Upper38.02 USD
BB Middle25.71 USD
BB Lower13.39 USD
BB Width95.81%
ATR (14)3.398 USD
Vol Ratio (20d)1.81x